Researchers on both sides of the border, within the Interreg Italy–Slovenia Immunocluster-2 (IC-2) project, have developed a platform for the preparation and testing of autologous immunohybridomas (aHyC-TNBC) for the treatment of triple-negative breast cancer (TNBC). The IC-2 project established a platform that enables patients in Slovenia to access advanced cancer therapy using the most advanced form of a fully personalized medicine, aHyC-TNBC, within a clinical study.
From September 2023 until the end of 2025, the following partners collaborated: the University of Udine, VivaBioCell, the University Hospital of Central Friuli, the Institute of Oncology Ljubljana, the Blood Transfusion Centre of Slovenia, and Celica as the lead partner.
In addition to preparations for delivering treatment with the advanced cellular therapy aHyC-TNBC, IC-2 has also resulted in the synchronization of advanced technologies for the production of human cells for therapy.
The results of IC-2 will allow the partners to continue collaborating on an upcoming clinical trial to test the safety and effectiveness of aHyC-TNBC in breast cancer treatment.
This represents a first for cooperation at the level of the entire European Union.
